BCHE and myasthenia gravis: In terms of treatment response, AChR-MG patients are more sensitive to cholinesterase inhibitors whereas MuSK-MG patients often require additional therapeutic interventions such as prednisone and other immunosuppressants; this difference between the 2 subtypes of MG may be attributable to differences in pathogenic mechanisms and disease severity [1, 3, 4].